Answers are grounded in this paper and cite their sources.
A neutralizing human monoclonal antibody, KZ52, protects guinea pigs from lethal Ebola Zaire virus challenge. Administration before or up to 1 h after challenge resulted in dose-dependent protection by the antibody. Interestingly, some antibody-treated animals survived despite developing high-level viremia, suggesting that the mechanism of protection by KZ52 may extend beyond reduction of viremia by virus neutralization. KZ52 is a promising candidate for immunoprophylaxis of Ebola virus infection.
No takes yet. Share an insight, caveat, or question.
Parren et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: